Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature

• Published in: Journal of the European Academy of Dermatology and Venereology 2006-01, Vol.20 (1), p.69-74
• Main Authors: Barnadas, MA, Roe, E, Brunet, S, Garcia, P, Bergua, P, Pimentel, L, Puig, L, Francia, A, García, R, Gelpí, C, Sierra, J, Coll, P, Alomar, A
• Format: Article
• Language: English
• Subjects: Aged; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents - therapeutic use; B‐cell lymphoma; Fatal Outcome; Female; Humans; Mycobacterium chelonae; paraneoplastic pemphigus; Paraneoplastic Syndromes - drug therapy; Paraneoplastic Syndromes - pathology; Pemphigus - drug therapy; Pemphigus - pathology; Rituximab; therapy
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/j.1468-3083.2005.01345.x

Paraneoplastic pemphigus (PNP) is an autoimmune blistering disease with poor prognosis when associated with malignant neoplasm. We report the case of a patient with PNP associated with a CD20+ non‐Hodgkin follicular lymphoma who was treated with Rituximab plus corticosteroids and short courses of cyclosporin. One and a half years after Rituximab therapy, oral ulcerations had cleared and oral methylprednisolone was slowly tapered down without further recurrences. In the course of the disease, the patient developed sepsis due to Listeria monocytogenes and viral infections by human herpes virus 1 and 3. At the end‐stage of the disease she developed a cutaneous infection from Mycobacterium chelonae. The patient died 2 years and 7 months after the onset of PNP. Rituximab may be useful for PNP therapy, but further studies are necessary to confirm this hypothesis.